Neill Iscoe

Author PubWeight™ 7.56^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.	Cancer	2006	2.44
2	Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.	Clin Cancer Res	2003	0.92
3	A letter from CMAJ's editorial board to the CMA.	CMAJ	2002	0.90
4	Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer.	J Thorac Oncol	2010	0.90
5	Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100.	Cancer	2006	0.86
6	Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.	Breast Cancer Res Treat	2010	0.84
7	Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.	Int J Radiat Oncol Biol Phys	2010	0.83
8	Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients.	Support Care Cancer	2004	0.75
9	A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.	Cancer Chemother Pharmacol	2009	0.75